Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor

About this update from Insulet Corporation

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery (AID) System. The updates follow FDA 510(k) clearance in December 2025. Omnipod 5 is also now compatible in the U.S. with Abbott’s Libre 3 Plus sensor, expanding choice for people with diabetes. “Delivering innovations that make diabetes management easier is at the heart of everything we do. These enhancements deliver what users tell us matters most—smarter automation, more personalization, better control, and expanded choice,” said Eric Benjamin, Insulet Executive Vice President and Chief Operating Officer. “By offering a lower target glucose option and expanding sensor compatibility, we’re helping people spend less time making decisions about diabetes and more time feeling confident, supported, and in control.” Enhanced Omnipod 5 Algorithm Now Available in the U.S. As the most significant algorithm advancement since its launch in 2022, the updated Omnipod 5 algorithm allows all U.S. users — new and existing — to benefit from improved automation and system performance. It adds a new 100 mg/dL Target Glucose option, providing more personalization and giving healthcare providers greater flexibility to finetune care with six settings from 100–150 mg/dL. Real-world evidence shows that lowering Target Glucose increases time in range (TIR) without a clinically meaningful rise in time below range1. The enhanced Omnipod 5 algorithm also helps users stay in Automated Mode with fewer interruptions, even during prolonged high glucose events. To help users benefit from the new 100 mg/dL Target Glucose as soon as possible, Insulet began shipping compatible Pods into U.S. retail channels ahead of the rollout. Omnipod 5 users will receive an over-the-air software update through their Omnipod 5 Controller or mobile app, with access to new features expanding as compatible Pods become available. Expanded Sensor Choice with Abbott’s Libre 3 Plus Sensor Compatibility Insulet is also rolling out U.S. compatibility between Omnipod 5 and Abbott’s Libre 3 Plus sensor with the ability for caregivers to follow patients through Abbott’s LibreLinkup app, giving users more sensor choice and making automated insulin delivery eas...

View stock analysis, news, and events for Insulet Corporation